Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

PP405 is being discussed as a promising hair loss treatment, potentially effective when combined with minoxidil and pyrilutamide. Some users are skeptical about rapid hair regrowth claims, while others are considering alternatives like GT20029 and pyrilutamide instead of finasteride.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

A user shared their positive experience using finasteride and minoxidil at 36, after having unpleasant side effects at 18. They report no current side effects and are seeing good progress with their hair, including using microneedling weekly.

A user traveled to Turkey to buy 72 packages of Dutasteride for a year-long supply and successfully brought them back home. They plan to use 2.5mg of Dutasteride daily along with RU58841 for hair loss.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The conversation discusses using a TCA 35% chemical peel on the scalp to potentially improve hair growth by addressing fibrosis and enhancing the effectiveness of topical treatments. The user also mentions trying microneedling and other methods like topical metformin and dutasteride for hair regrowth.

The user tried a product labeled as PP405 from Umbrella Labs for hair loss but saw no changes, and it was revealed to be a fake or misidentified product. The user is also using finasteride, minoxidil, and other treatments but is still experiencing hairline issues.

KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

The conversation is about purchasing Cb-03-01 for research purposes. The user seeks advice on where and how to buy it outside the U.S.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

KX-826 stopped hair loss for the user after stopping finasteride due to mild side effects. The user experienced mild headaches initially with KX-826, which resolved after a few days.

A 26-year-old experienced significant hairline regrowth in 4 months using 1 mg finasteride and 3 mg oral minoxidil, with additional weekly derma stamping. Minoxidil was credited for the regrowth, with noticeable results appearing 3-4 weeks after starting the treatment.

The conversation humorously discusses hair regrowth using PP405, with jokes about side effects and secret hair transplants. The user claims no side effects except craving cheese.

PP405 now has a Wikipedia page, generating more discussion and attention. One user plans to continue using finasteride until PP405 is proven effective and widely available.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

A 35-year-old shared a 7-day update on their hair transplant, which involved 3,153 grafts performed by Dr. Elif at HLC Ankara, costing 10,000 euros including accommodations. The user has been on finasteride for over 12 years and opted for a partial shave FUE to address hairline recession and temple peaks.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

A user shared a positive 6-month update after a hair transplant with MCAN in Turkey, using the Sapphire FUE method with 4000 grafts from the back and side of the head. The user is pleased with the natural-looking hairline and new growth, recommending the clinic for its professionalism and support.